BioRestorative Therapies to Announce Financial Results
MELVILLE, N.Y. — BioRestorative Therapies, Inc. (“BioRestorative” or “BRTX”) (NASDAQ: BRTX), a pioneering innovator in regenerative medicine focused on stem cell-based therapies, is gearing up to release its financial results for the second quarter of 2025. This highly anticipated announcement is set to take place after the market closes on Tuesday, August 12, 2025. Following this release, the management team will be hosting a conference call to discuss the financial outcomes and provide an update on the company's business initiatives.
Details About the Conference Call
The specifics for the conference call are as follows:
Date and Time
The call is scheduled for Tuesday, August 12, 2025, at 4:30 p.m. Eastern Time.
Dial-In Information
Participants can join via the following numbers:
- Domestic: 1-888-506-0062
- International: 1-973-528-0011
- Access Code: 436077
This call will provide an opportunity for participants to hear directly from BioRestorative's management, who will outline financial performance and business strategies moving forward.
Accessing the Call
The call will also be broadcast live and made available for archival listening on the Company’s website under the Investors section, specifically in the News & Events/IR Calendar area. This allows stakeholders and interested parties to stay in the loop about BioRestorative's developments.
About BioRestorative Therapies, Inc.
BioRestorative Therapies, located at www.biorestorative.com, is committed to developing unique therapeutic products that utilize cell and tissue protocols, with a strong focus on adult stem cells. The company is currently advancing two main clinical development programs that target spine and metabolic health:
Disc/Spine Program (brtxDISC™)
The company's flagship cell therapy product, BRTX-100, utilizes cultured mesenchymal stem cells sourced from the patient's own bone marrow. This innovative therapy is designed as a non-surgical option for managing painful lumbosacral disc disorders and can also be a complementary solution alongside surgical treatments. The production process for BRTX-100 is proprietary, involving the patient’s own cells to promote healing and recovery. A Phase 2 clinical trial is underway, focusing on chronic lower back pain linked to degenerative disc disease. Additionally, the company has secured FDA clearance to conduct trials evaluating the efficacy of BRTX-100 in treating chronic cervical disc pain.
Metabolic Program (ThermoStem)
BioRestorative is also delving into cellular therapies aimed at addressing obesity and metabolic conditions. This involves the use of brown adipose-derived stem cells to promote the development of brown adipose tissue. Early preclinical findings suggest that increasing brown fat could enhance calorie burning and improve glucose and lipid levels, potentially lowering diabetes and obesity risks. The insights being gathered here could significantly impact metabolic health solutions.
BioCosmeceuticals
In addition, the company is proud to offer a BioCosmeceutical platform featuring a cutting-edge product developed under cGMP standards in an ISO-7 certified environment. This serum, rich in exosomes, proteins, and growth factors, is specifically formulated to enhance cosmetic appearance by reducing fine lines and enhancing skin quality. BioRestorative aims to expand this segment, planning further IND-enabling studies to secure FDA approvals for a broader range of aesthetic applications.
Frequently Asked Questions
What date will BioRestorative announce its financial results?
BioRestorative will announce its financial results for the second quarter on August 12, 2025.
How can I join the conference call?
Participants can join the call by dialing 1-888-506-0062 for domestic calls and 1-973-528-0011 for international calls, using access code 436077.
What is the main focus of BioRestorative?
BioRestorative focuses on developing stem cell-based therapies and products aimed at addressing spine and metabolic health issues.
Where can I find more information about the company’s products?
More information can be found on BioRestorative's website, particularly in the Investors section.
What is the significance of BRTX-100?
BRTX-100 is BioRestorative's lead therapy aimed at treating chronic lower back pain through innovative regenerative techniques.
